ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE

An objective of the invention is to provide anti-latent TGF-beta 1 antibodies and methods of using such antibodies. The present invention provides anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of la...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MORI, Keita, SHIRAI, Kazuhide, TAKIZAWA, Shuuki, IKAWA, Yuri, SAVORY, Nasa, KANAMORI, Masakazu
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An objective of the invention is to provide anti-latent TGF-beta 1 antibodies and methods of using such antibodies. The present invention provides anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 or with partially inhibiting integrin mediated activation of latent TGF-beta 1, or which inhibit a protease mediated activation of latent TGF-beta 1 but have less impact on inhibiting integrin mediated activation of latent TGF-beta 1. The invention also provides optimized anti-latent TGF-beta 1 antibodies in which pH-dependent binding property is improved. The anti-latent TGF-beta 1 antibodies may be used for treating fibrosis or cancer. For example, renal fibrosis, liver fibrosis, and lung fibrosis may be treated using the anti-latent TGF-beta 1 antibodies.